{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:44:44Z","timestamp":1792107884327,"version":"4.4.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In response to the devastating drug toxicity crisis in Canada driven by an unregulated opioid supply predominantly composed of fentanyl and analogues, safer supply programs have been introduced. These programs provide people using street-acquired opioids with prescribed, pharmaceutical opioids. We use six core components of safer supply programs identified by people who use drugs to explore participant perspectives on the first year of operations of a safer supply program in Victoria, BC, during the dual public health emergencies of COVID-19 and the drug toxicity crisis to examine whether the program met drug-user defined elements of an effective safer supply model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study used a community-based participatory research approach to ensure that the research was reflective of community concerns and priorities, rather than being extractive. We interviewed 16 safer supply program participants between December 2020 and June 2021. Analysis was structured using the six core components of effective safer supply from the perspective of people who use drugs, generated through a prior study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Ensuring access to the \u2018right dose and right drugs\u2019 of medications was crucial, with many participants reporting success with the available pharmaceutical options. However, others highlighted issues with the strength of the available medications and the lack of options for smokeable medications. Accessing the safer supply program allowed participants to reduce their use of drugs from unregulated markets and manage withdrawal, pain and cravings. On components related to program operations, participants reported receiving compassionate care, and that accessing the safer supply program was a non-stigmatizing experience. They also reported receiving support to find housing, access food, obtain ID, and other needs. However, participants worried about long term program sustainability.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Participants in the safer supply program overwhelmingly appreciated it and felt it was lifesaving, and unlike other healthcare or treatment services they had previously accessed. Participants raised concerns that unless a wider variety of medications and ability to consume them by multiple routes of administration became available, safer supply programs would remain unable to completely replace substances from unregulated markets.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-024-01029-3","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T04:01:50Z","timestamp":1717732910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["\u201cIf it wasn\u2019t for them, I don\u2019t think I would be here\u201d: experiences of the first year of a safer supply program during the dual public health emergencies of COVID-19 and the drug toxicity crisis"],"prefix":"10.1186","volume":"21","author":[{"given":"Gillian","family":"Kolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernie","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Ranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Majalahti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Toombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"LeMaistre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Selfridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Urbanoski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"1029_CR1","unstructured":"BC Coroner\u2019s Service. Unregulated Drug Deaths in B.C. 2023. Available from: https:\/\/www2.gov.bc.ca\/gov\/content\/life-events\/death\/coroners-service\/statistical-reports"},{"key":"1029_CR2","unstructured":"BC Coroner\u2019s Service Death Panel Review. BC Coroner\u2019s Service Death Panel Review: An Urgent Response to a Continuing Crisis. 2023 Nov 1; Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/death-review-panel\/an_urgent_response_to_a_continuing_crisis_report.pdf"},{"issue":"106","key":"1029_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103742","volume":"1","author":"S Glegg","year":"2022","unstructured":"Glegg S, McCrae K, Kolla G, Touesnard N, Turnbull J, Brothers TD, et al. \u201cCOVID just kind of opened a can of whoop-ass\u201d: the rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. Int J Drug Policy. 2022;1(106): 103742.","journal-title":"Int J Drug Policy"},{"issue":"36","key":"1029_CR4","doi-asserted-by":"publisher","first-page":"E1233","DOI":"10.1503\/cmaj.220892","volume":"194","author":"T Gomes","year":"2022","unstructured":"Gomes T, Kolla G, McCormack D, Sereda A, Kitchen S, Antoniou T. Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario. CMAJ. 2022;194(36):E1233\u201342.","journal-title":"CMAJ"},{"issue":"120","key":"1029_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104157","volume":"1","author":"M Karamouzian","year":"2023","unstructured":"Karamouzian M, Rafat B, Kolla G, Urbanoski K, Atkinson K, Bardwell G, et al. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: a qualitative analysis. Int J Drug Policy. 2023;1(120): 104157.","journal-title":"Int J Drug Policy"},{"key":"1029_CR6","unstructured":"BC Centre on Substance Use. Heroin Compassion Clubs [Internet]. 2019. Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2019\/02\/Report-Heroin-Compassion-Clubs.pdf"},{"key":"1029_CR7","unstructured":"Canadian Association of People who Use Drugs. Safe Supply Concept Document. 2019."},{"key":"1029_CR8","unstructured":"Medrano K. DULF Keeps Distributing Checked Drugs as Health Canada Flags Denial [Internet]. Filter. 2022. Available from: https:\/\/filtermag.org\/dulf-safe-supply-compassion-club-exemption\/"},{"key":"1029_CR9","unstructured":"Wyton M. The Tyee. 2022 [cited 2023 Dec 21]. Health Canada Denies Compassion Club Exemption for Safe Supply. Available from: https:\/\/thetyee.ca\/News\/2022\/09\/01\/Health-Canada-Denies-Compassion-Club-Exemption-Safe-Supply\/"},{"key":"1029_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104330","volume":"22","author":"J Kalicum","year":"2024","unstructured":"Kalicum J, Nyx E, Kennedy MC, Kerr T. The impact of an unsanctioned compassion club on non-fatal overdose. Int J Drug Policy. 2024;22: 104330.","journal-title":"Int J Drug Policy"},{"key":"1029_CR11","unstructured":"Drug User Liberation Front (DULF). 2023. DULF Compassion Club Preliminary Findings. Available from: https:\/\/www.dulf.ca\/cc-preliminary-findings"},{"key":"1029_CR12","doi-asserted-by":"crossref","unstructured":"Macevicius C, Gudi\u00f1o P\u00e9rez D, Norton A, Kolla G, Beck-McGreevy P, Selfridge M, et al. Just have this come from their prescription pad: the medicalization of safer supply from the perspectives of health planners in BC, Canada. Drugs: Education, Prevention and Policy. 2023;0(0):1\u201311.","DOI":"10.1080\/09687637.2023.2283383"},{"key":"1029_CR13","unstructured":"Kolla G, Long C, Perri M, Bowra A, Penn R. Safer Opioid Supply Program: Preliminary Report [Internet]. London: London Intercommunity Health Center; 2021 Nov p. 44. Available from: https:\/\/lihc.on.ca\/wp-content\/uploads\/2022\/01\/2021-SOS-Evaluation-Full.pdf"},{"key":"1029_CR14","unstructured":"BC Centre on Substance Use. Risk Mitigation In the Context of Dual Public Health Emergencies. 2022. Available from: https:\/\/www.bccsu.ca\/wp-content\/uploads\/2022\/02\/Risk-Mitigation-Guidance-Update-February-2022.pdf"},{"key":"1029_CR15","unstructured":"Atkinson K. Parkdale Queen West Community Health Center Safer Opioid Supply: 2023 Evaluation Report [Internet]. 2023 Mar. Available from: https:\/\/pqwchc.org\/ programs-services\/harm-reduction\/safer-opioidsupply-sos-program"},{"key":"1029_CR16","unstructured":"Haines M, Tefoglou A, O\u2019Byrne P. Safer Supply Ottawa Evaluation [Internet]. Ottawa; 2022 p. 55. Available from: https:\/\/safersupplyottawa.com\/wp-content\/uploads\/SS-Ottawa-Evaluation-Report-Fall-2022.pdf"},{"issue":"1","key":"1029_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11524-020-00489-9","volume":"98","author":"A Ivsins","year":"2021","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. \u201cIt\u2019s helped me a lot, just like to stay alive\u201d: a qualitative analysis of outcomes of a novel hydromorphone tablet distribution program in vancouver. Canada J Urban Health. 2021;98(1):59\u201369.","journal-title":"Canada J Urban Health"},{"key":"1029_CR18","unstructured":"McMurchy D, Palmer RW. Assessment of the Implementation of Safer Supply Pilot Projects [Internet]. Ottawa, Ontario; 2022 Mar p. 88. Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/responding-canada-opioid-crisis\/safer-supply\/early-findings-safer-supply-pilot-projects.html"},{"issue":"S2","key":"1029_CR19","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.2105\/AJPH.2021.306692","volume":"112","author":"R McNeil","year":"2022","unstructured":"McNeil R, Fleming T, Mayer S, Barker A, Mansoor M, Betsos A, et al. Implementation of safe supply alternatives during intersecting COVID-19 and overdose health emergencies in British Columbia, Canada, 2021. Am J Public Health. 2022;112(S2):S151\u20138.","journal-title":"Am J Public Health"},{"key":"1029_CR20","unstructured":"Ranger C, Hobbs H, Cameron F, Stuart H, McCall J, Sullivan G, et al. Co\/Lab Practice Brief: Implementing the Victoria SAFER Initiative [Internet]. Canadian Institute for Substance Use Research, University of Victoria; 2021 p. 12. Available from: https:\/\/www.uvic.ca\/research\/centres\/cisur\/assets\/docs\/colab\/practice-brief-safer.pdf"},{"key":"1029_CR21","doi-asserted-by":"publisher","unstructured":"Schmidt RA, Kaminski N, Kryszajtys DT, Rudzinski K, Perri M, Guta A, et al. \u2018I don\u2019t chase drugs as much anymore, and I\u2019m not dead\u2019: Client reported outcomes associated with safer opioid supply programs in Ontario, Canada. Drug and Alcohol Review [Internet]. 2023 [cited 2023 Sep 25];n\/a(n\/a). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/https:\/\/doi.org\/10.1111\/dar.13745","DOI":"10.1111\/dar.13745"},{"issue":"384","key":"1029_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076336","volume":"11","author":"A Slaunwhite","year":"2024","unstructured":"Slaunwhite A, Min JE, Palis H, Urbanoski K, Pauly B, Barker B, et al. Effect of Risk Mitigation Guidance opioid and stimulant dispensations on mortality and acute care visits during dual public health emergencies: retrospective cohort study. BMJ. 2024;11(384): e076336.","journal-title":"BMJ"},{"issue":"110","key":"1029_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103849","volume":"1","author":"B Pauly","year":"2022","unstructured":"Pauly B, McCall J, Cameron F, Stuart H, Hobbs H, Sullivan G, et al. A concept mapping study of service user design of safer supply as an alternative to the illicit drug market. Int J Drug Policy. 2022;1(110): 103849.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"1029_CR24","first-page":"ii3","volume":"82","author":"M Minkler","year":"2005","unstructured":"Minkler M. Community-based research partnerships: challenges and opportunities. J Urban Health. 2005;82(2):ii3-12.","journal-title":"J Urban Health"},{"issue":"S1","key":"1029_CR25","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.2105\/AJPH.2009.165720","volume":"100","author":"M Minkler","year":"2010","unstructured":"Minkler M. Linking science and policy through community-based participatory research to study and address health disparities. Am J Public Health. 2010;100(S1):S81\u20137.","journal-title":"Am J Public Health"},{"issue":"1","key":"1029_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12954-023-00852-4","volume":"20","author":"P Beck McGreevy","year":"2023","unstructured":"Beck McGreevy P, Wood S, Thomson E, Burmeister C, Spence H, Pelletier J, et al. Doing community-based research during dual public health emergencies (COVID and overdose). Harm Reduct J. 2023;20(1):135.","journal-title":"Harm Reduct J"},{"issue":"98","key":"1029_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103533","volume":"1","author":"M Harris","year":"2021","unstructured":"Harris M, Luongo N. \u201cNothing about us, without us\u201d: negotiating the personal and professional as activists and academics who use drugs. Int J Drug Policy. 2021;1(98): 103533.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"1029_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048353","volume":"11","author":"B Nosyk","year":"2021","unstructured":"Nosyk B, Slaunwhite A, Urbanoski K, Hongdilokkul N, Palis H, Lock K, et al. Evaluation of risk mitigation measures for people with substance use disorders to address the dual public health crises of COVID-19 and overdose in British Columbia: a mixed-method study protocol. BMJ Open. 2021;11(6): e048353.","journal-title":"BMJ Open"},{"issue":"235","key":"1029_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109440","volume":"1","author":"TD Brothers","year":"2022","unstructured":"Brothers TD, Leaman M, Bonn M, Lewer D, Atkinson J, Fraser J, et al. Evaluation of an emergency safe supply drugs and managed alcohol program in COVID-19 isolation hotel shelters for people experiencing homelessness. Drug Alcohol Depend. 2022;1(235): 109440.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1029_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12954-022-00614-8","volume":"19","author":"B Lew","year":"2022","unstructured":"Lew B, Bodkin C, Lennox R, O\u2019Shea T, Wiwcharuk G, Turner S. The impact of an integrated safer use space and safer supply program on non-fatal overdose among emergency shelter residents during a COVID-19 outbreak: a case study. Harm Reduct J. 2022;19(1):29.","journal-title":"Harm Reduct J"},{"key":"1029_CR31","unstructured":"BC Coroner\u2019s Service. BC Coroners Service Death Review Panel: A Review of Illicit Drug Toxicity Deaths. 2022; Available from: https:\/\/www2.gov.bc.ca\/assets\/gov\/birth-adoption-death-marriage-and-divorce\/deaths\/coroners-service\/death-review-panel\/review_of_illicit_drug_toxicity_deaths_2022.pdf"},{"key":"1029_CR32","unstructured":"Gomes T, Murray R, Kolla G, Leece P, Bansal S, Besharah J, et al. Changing Circumstances Surrounding Opioid-Related Deaths in Ontario during the COVID-19 Pandemic. ODPRN. 2021. Available from: https:\/\/odprn.ca\/research\/publications\/opioid-related-deaths-in-ontario-during-covid\/"},{"issue":"1","key":"1029_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","volume":"18","author":"D Frank","year":"2021","unstructured":"Frank D, Mateu-Gelabert P, Perlman DC, Walters SM, Curran L, Guarino H. \u201cIt\u2019s like \u2018liquid handcuffs\u201d: the effects of take-home dosing policies on methadone maintenance treatment (MMT) patients\u2019 lives. Harm Reduct J. 2021;18(1):88.","journal-title":"Harm Reduct J"},{"issue":"S2","key":"1029_CR34","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.2105\/AJPH.2021.306665","volume":"112","author":"C Simon","year":"2022","unstructured":"Simon C, Vincent L, Coulter A, Salazar Z, Voyles N, Roberts L, et al. The methadone manifesto: treatment experiences and policy recommendations from methadone patient activists. Am J Public Health. 2022;112(S2):S117\u201322.","journal-title":"Am J Public Health"},{"issue":"7","key":"1029_CR35","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1080\/10826084.2022.2064509","volume":"57","author":"SM Walters","year":"2022","unstructured":"Walters SM, Perlman DC, Guarino H, Mateu-Gelabert P, Frank D. Lessons from the first wave of COVID-19 for improved medications for opioid use disorder (MOUD) treatment: benefits of easier access, extended take homes, and new delivery modalities. Subst Use Misuse. 2022;57(7):1144\u201353.","journal-title":"Subst Use Misuse"},{"issue":"216","key":"1029_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108202","volume":"1","author":"A Ivsins","year":"2020","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: a qualitative study. Drug Alcohol Depend. 2020;1(216): 108202.","journal-title":"Drug Alcohol Depend"},{"key":"1029_CR37","doi-asserted-by":"crossref","unstructured":"Magel T, Matzinger E, Blawatt S, Harrison S, MacDonald S, Amara S, et al. How injectable opioid agonist treatment (iOAT) care could be improved? service providers and stakeholders\u2019 perspectives. Drugs: Education, Prevention and Policy. 2023;1\u201312.","DOI":"10.1080\/09687637.2023.2176287"},{"issue":"117","key":"1029_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104054","volume":"1","author":"S Mayer","year":"2023","unstructured":"Mayer S, Boyd J, Fairbairn N, Chapman J, Brohman I, Jenkins E, et al. Women\u2019s experiences in injectable opioid agonist treatment programs in Vancouver, Canada. Int J Drug Policy. 2023;1(117): 104054.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1029_CR39","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12954-023-00785-y","volume":"20","author":"F Riley","year":"2023","unstructured":"Riley F, Harris M, Poulter HL, Moore HJ, Ahmed D, Towl G, et al. \u2018This is hardcore\u2019: a qualitative study exploring service users\u2019 experiences of Heroin-Assisted Treatment (HAT) in Middlesbrough, England. Harm Reduct J. 2023;20(1):66.","journal-title":"Harm Reduct J"},{"issue":"5","key":"1029_CR40","doi-asserted-by":"publisher","first-page":"556","DOI":"10.15288\/jsad.2020.81.556","volume":"81","author":"M Bonn","year":"2020","unstructured":"Bonn M, Palayew A, Bartlett S, Brothers TD, Touesnard N, Tyndall M. Addressing the syndemic of HIV, Hepatitis C, overdose, and COVID-19 among people who use drugs: the potential roles for decriminalization and safe supply. J Stud Alcohol Drugs. 2020;81(5):556\u201360.","journal-title":"J Stud Alcohol Drugs"},{"issue":"1","key":"1029_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13011-019-0227-0","volume":"14","author":"K Marchand","year":"2019","unstructured":"Marchand K, Beaumont S, Westfall J, MacDonald S, Harrison S, Marsh DC, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prevent Policy. 2019;14(1):37.","journal-title":"Subst Abuse Treat Prevent Policy"},{"issue":"123","key":"1029_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108276","volume":"1","author":"MC Figgatt","year":"2021","unstructured":"Figgatt MC, Salazar Z, Day E, Vincent L, Dasgupta N. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. J Subst Abuse Treat. 2021;1(123): 108276.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"1029_CR43","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","volume":"16","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16(1):68.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"1029_CR44","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","volume":"8","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, Levin E, Dooling BCE. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy. The Lancet Public Health. 2023;8(3):e238\u201346.","journal-title":"The Lancet Public Health"},{"key":"1029_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103548","volume":"101","author":"M Meyer","year":"2022","unstructured":"Meyer M, Strasser J, K\u00f6ck P, Walter M, Vogel M, D\u00fcrsteler KM. Experiences with take-home dosing in heroin-assisted treatment in Switzerland during the COVID-19 pandemic-Is an update of legal restrictions warranted? Int J Drug Policy. 2022;101: 103548.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1029_CR46","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12913-023-09558-6","volume":"23","author":"E Oviedo-Joekes","year":"2023","unstructured":"Oviedo-Joekes E, Dobischok S, Carvajal J, MacDonald S, McDermid C, Klakowicz P, et al. Clients\u2019 experiences on North America\u2019s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study. BMC Health Serv Res. 2023;23(1):553.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"1029_CR47","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jama.2022.1271","volume":"327","author":"T Gomes","year":"2022","unstructured":"Gomes T, Campbell TJ, Kitchen SA, Garg R, Bozinoff N, Men S, et al. Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation. JAMA. 2022;327(9):846\u201355.","journal-title":"JAMA"},{"issue":"5","key":"1029_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.11389","volume":"7","author":"JE Min","year":"2024","unstructured":"Min JE, Guerra-Alejos BC, Yan R, Palis H, Barker B, Urbanoski K, et al. Opioid coprescription through risk mitigation guidance and opioid agonist treatment receipt. JAMA Netw Open. 2024;7(5): e2411389.","journal-title":"JAMA Netw Open"},{"key":"1029_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104075","volume":"22","author":"ME Socias","year":"2023","unstructured":"Socias ME, Choi JC, Fairbairn N, Johnson C, Wilson D, Debeck K, et al. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: an interrupted time series analysis. Int J Drug Policy. 2023;22: 104075.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"1029_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12954-024-00935-w","volume":"21","author":"G Kolla","year":"2024","unstructured":"Kolla G, Tarannum CN, Fajber K, Worku F, Norris K, Long C, et al. Substance use care innovations during COVID-19: barriers and facilitators to the provision of safer supply at a toronto COVID-19 isolation and recovery site. Harm Reduct J. 2024;21(1):17.","journal-title":"Harm Reduct J"},{"key":"1029_CR51","unstructured":"Pauly B. Chapter 9. Close to the Street: Nursing Practice with People Marginalized by Homelessness and Substance Use. In: Guirguis-Younger M, Hwang SW, McNeil R, editors. Homelessness & Health in Canada. Ottawa: Les Presses de l\u2019Universit\u00e9 d\u2019Ottawa | University of Ottawa Press; 2017. p. 211\u201332. (Sant\u00e9 et soci\u00e9t\u00e9 | Health and Society). Available from: http:\/\/books.openedition.org\/uop\/805"},{"issue":"5","key":"1029_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229208","volume":"15","author":"B Pauly","year":"2020","unstructured":"Pauly B, Wallace B, Pagan F, Phillips J, Wilson M, Hobbs H, et al. Impact of overdose prevention sites during a public health emergency in Victoria, Canada. PLoS One. 2020;15(5): e0229208.","journal-title":"PLoS One"},{"issue":"3","key":"1029_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.drugpo.2008.02.009","volume":"19","author":"B Pauly","year":"2008","unstructured":"Pauly B. Shifting moral values to enhance access to health care: Harm reduction as a context for ethical nursing practice. Int J Drug Policy. 2008;19(3):195\u2013204.","journal-title":"Int J Drug Policy."},{"issue":"1","key":"1029_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13011-023-00515-4","volume":"18","author":"A Kamal","year":"2023","unstructured":"Kamal A, Ferguson M, Xavier JC, Liu L, Graham B, Lock K, et al. Smoking identified as preferred mode of opioid safe supply use; investigating correlates of smoking preference through a 2021 cross-sectional study in British Columbia. Subst Abuse Treat Prevent Policy. 2023;18(1):27.","journal-title":"Subst Abuse Treat Prevent Policy"},{"key":"1029_CR55","unstructured":"Kolla G, Fajber K. Safer Opioid Supply Program: A Comparison of SOS Client Outcomes From 2022 and 2023. Ontario, Canada: London Intercommunity Health Center; 2023. Available from: https:\/\/www.nss-aps.ca\/sites\/default\/files\/resources\/2023-LIHC-SOS-Evaluation.pdf"},{"key":"1029_CR56","unstructured":"Xavier J, McGreevy P, McDougall J, Lamb J, A S, Haywood B, et al. Substance Use Patterns and Safer Supply Preferences Among People Who Use Drugs in British Columbia. 2023."},{"key":"1029_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104197","volume":"22","author":"M MacDonald","year":"2023","unstructured":"MacDonald M, Cheng C, Wang T, McCormack D, Kolla G, Cahill TM, et al. Trends in varying modes of drug use in opioid toxicity deaths in Ontario from 2017 to 2021. Int J Drug Policy. 2023;22: 104197.","journal-title":"Int J Drug Policy"},{"issue":"12","key":"1029_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295145","volume":"18","author":"S Young","year":"2023","unstructured":"Young S, Gomes T, Kolla G, McCormack D, Dodd Z, Raboud J, et al. Initiations of safer supply hydromorphone increased during the COVID-19 pandemic in Ontario: An interrupted time series analysis. PLoS One. 2023;18(12): e0295145.","journal-title":"PLoS One"},{"key":"1029_CR59","unstructured":"Letter: More than 130 experts in substance use call on federal government to continue to support and scale-up safer supply programs. 2023. Available from: https:\/\/www.hivlegalnetwork.ca\/site\/letter-more-than-130-experts-in-substance-use-call-on-federal-government-to-continue-to-support-and-scale-up-safer-supply-programs\/?lang=en"},{"issue":"127","key":"1029_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104423","volume":"1","author":"L Michaud","year":"2024","unstructured":"Michaud L, Kolla G, Rudzinski K, Guta A. Mapping a moral panic: news media narratives and medical expertise in public debates on safer supply, diversion, and youth drug use in Canada. Int J Drug Policy. 2024;1(127): 104423.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01029-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01029-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T04:04:34Z","timestamp":1717733074000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01029-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01029-3","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]},"assertion":[{"value":"20 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors obtained all required ethical approvals for the work reported in this paper. The University of Victoria Research Ethics Board approved this study. Informed consent was obtained from all participants prior to their participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}